Tafamidis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | <scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | ||
<scene name='10/1006890/Binding_site/1'>Tafamidis binding site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 15:42, 6 November 2023
Tafamidis, sold under the brand names Vyndaqel and Vyndamax,[1] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people with transthyretin amyloidosis, transthyretin falls apart and forms clumps called (amyloid) that harm tissues including nerves and the heart.[2][3] (3tct). .
|
| ||||||||||
ReferencesReferences
- ↑ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Retrieved 24 November 2019
- ↑ "Vyndaqel EPAR". European Medicines Agency. 16 October 2019. Retrieved 24 November 2019.
- ↑ "FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis". U.S. Food and Drug Administration. 14 September 2019. Archived from the original on 14 September 2019.